Single-cell spatial analysis of pediatric high-grade glioma reveals a novel population of SPP1 + /GPNMB + myeloid cells with immunosuppressive and tumor-promoting capabilities

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Pediatric-type diffuse high-grade gliomas (pHGG) are a leading cause of pediatric cancer-related mortality. Although immunotherapy offers a promising treatment avenue, clinical responses in pHGG patients remain limited. A detailed understanding of the tumor immune microenvironment (TIME) is essential for advancing immunotherapeutic strategies.

Methods

We performed single-cell spatial analysis integrating cyclical immunofluorescence imaging and Spatial Molecular Imaging to interrogate the proteomic and transcriptomic landscape of pHGG. A tissue microarray comprising 32 diagnostic patient-derived pHGG samples was utilized to map the spatial distribution of immune and tumor cells.

Results

Our analyses reveal that the pHGG TIME is predominantly composed of myeloid cells, including brain-resident microglia and monocyte-derived macrophages, with only few T cells. A significant subset of these myeloid cells express mesenchymal-like genes and are positive for SPP1 and GPNMB. Spatial mapping further demonstrated that SPP1 + /GPNMB + myeloid cells localize in close proximity to mesenchymal-like tumor cells, and negatively correlate with the location and presence of CD8 + T cells. These cells also express genes related to immunosuppression and epithelial-to-mesenchymal transition, indicating their potential role in establishing an immunosuppressive niche.

Conclusions

Our findings reveal a distinct immune landscape in pHGG characterized by SPP1 + /GPNMB + myeloid cells which may contribute to the exclusion of CD8 + T cells. This spatially resolved insight identifies these myeloid cells as promising therapeutic targets and provides a rationale for developing novel immunotherapeutic strategies to improve outcomes in pediatric high-grade gliomas.

Article activity feed